|
|
|
| Application of immunonutrition in radiotherapy and chemotherapy of digestive tract malignant tumor |
| Huang Yong ,Xie Ming, Wang Jiwei |
| Department of Gastrointestinal Surgery Affiliated Hospital of Zunyi Medical University Zunyi 56300 Guizhou China |
|
|
|
|
Abstract In China the morbidity and mortality of digestive tract malignant tumors are always at a high level and surgery radiotherapy and chemotherapy are the main treatment methods. Studies have found that 50%-70% of patients with digestive tract malignant
tumors are at risk of malnutrition due to the bodys high metabolism and stress response. The risk of malnutrition increases especially
in older patients undergoing surgery or chemotherapy. Anorexia nausea vomiting and absorption disorders caused by radiotherapy and
chemotherapy easily lead to weight loss and malnutrition risk or malnutrition of patients increase the occurrence of adverse reactions to
radiotherapy and chemotherapy resulting in reduced efficacy or even treatment interruption thus affecting the quality of life and prognosis of patients. Therefore nutritional therapy is very important for tumor patients with radiotherapy and chemotherapy. In recent
years immunonutrients have been widely used in the nutrition of patients with digestive tract malignant tumors and have become a developing direction of tumor nutrition therapy. The immune nutrition helps to improve the immune function in patients with digestive tract
malignant tumor radiation and chemotherapy and inflammation levels enhance the sensitivity and tolerability of radiation and chemotherapy patients improve chemotherapy treatment improve the patients life quality prolong the survival period etc. but the immune
effect of nutrition in the digestive tract malignant tumor radiation and chemotherapy patients reported is differ still to be further study.
In this paper the research status of immunonutrition in patients with gastrointestinal malignancy was reviewed in order to explore the
ideal therapeutic strategy of immunonutrition for patients with gastrointestinal malignancy and provide potential reference value for improving patients' quality of life and disease outcome in the future.
|
|
Received: 12 January 2022
|
|
|
|
|
|
|
